CapTemY90 for Grade 2/3 NET Liver Metastases

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.

Trial Details

NCT ID
NCT04339036
Phase
PHASE2
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Capecitabine Oral Product
  • Temozolomide Oral Product
  • transarterial radioembolization
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Miami, Florida, United States|25.77427,-80.19366
  • Buffalo, New York, United States|42.88645,-78.87837
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Patients with confirmed diagnosis of histologic grade 2 or 3 well differentiated neuroendocrine tumor with unresectable liver metastases (primary t…
  • Patients with at least one measurable liver metastases, with size \> 1cm (RECIST criteria)
  • Patients with liver dominant disease defined as ≥50% tumor body burden confined to the liver
  • Liver tumor burden does not exceed 50% of the liver volume

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →